Pharma, Healthcare Q3 Earnings Preview - Subdued Quarter; Cost Headwinds To Curtail Margins: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
We expect pharma and healthcare companies under our coverage to report subdued growth during the quarter ended December 2021 (Q3 FY22), mainly due to higher raw material and freight cost as well as pricing pressure in the U.S. business amid inventory destocking.
We estimate the India business to grow in high single to low double digit as per secondary sales data, broadly in line with the industry. We forecast the Ebitda margin of covered companies at 22.1% (down 186 basis points YoY) due to cost inflation and price erosion in the U.S.
Hospitals and diagnostics are expected to report healthy YoY rise on a low base but decline QoQ due to seasonality and decline in Covid-19 cases. Overall, we expect coverage universe to report 5.9% YoY revenue growth, while Ebitda is expected to decline by 3.2% YoY.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.